Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (May 2023)
17 slides from Invivyd's investor presentation, May 2, 2023
Slide 1: Corporate Overview May 2023
Exhibit 99.1 Corporate Overview May 2023
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Urgent need for new therapeutics to protect immunocompromised people from COVID-19
THERE IS AN URGENT NEED FOR NEW THERAPEUTICS THAT PROTECT IMMUNOCOMPROMISED PEOPLE FROM COVID-19 Now, many people who are not well- “ protected by vaccines are in a dangerous and isolating situation—especially because the arsenal of effective COVID-19 treatments is shrinking for everyone as the viru
Slide 4: Millions of immunocompromised people may not adequately respond to COVID-19 vaccines
MILLIONS OF IMMUNOCOMPROMISED PEOPLE MAY NOT ADEQUATELY RESPOND TO COVID-19 VACCINES AND MAY BE AT HIGHER RISK FOR SEVERE OUTCOMES 1-3 8-18M people in the U.S. 4 14M people in the E.U. Organ are estimated to be immunocompromised due to transplant a medical condition or immunosuppressive recipients m
Slide 5: Prevention of COVID-19 in vulnerable populations is a large opportunity
PREVENTION OF COVID-19 IN VULNERABLE POPULATIONS IS A LARGE OPPORTUNITY $2.2B in total revenue of Evusheld® in 2022, a monoclonal antibody (mAb) previously authorized to protect vulnerable populations from COVID-19 $1,400 $1,270M $1,200 $1,000 $914M $800 $600 $400 $135M $200 $0 H2 2021 H1 2022 H2 20
Slide 6: Monoclonal antibodies play a critical role in the COVID-19 medicine cabinet
MONOCLONAL ANTIBODIES PLAY A CRITICIAL ROLE IN THE COVID-19 MEDICINE CABINET PREVENTION TREATMENT Vaccines mAbs Antivirals Anti-SARS-CoV-2 mAbs are expected to provide: Limitations for the • Rapid, passive immunity Limitations for the immunocompromised: immunocompromised: • Utility for prevention or
Slide 7: Invivyd is on a mission to rapidly and perpetually deliver monoclonal antibodies
INVIVYD IS ON A MISSION TO RAPIDLY AND PERPETUALLY DELIVER MONOCLONAL ANTIBODIES THAT HELP PROTECT THE VULNERABLE FROM COVID-19 Previous mAbs for the prevention of Combining expertise in virology, COVID-19 in vulnerable populations, such antibody engineering and predictive as immunocompromised peopl
Slide 8: Platform designed to rapidly deliver a stream of monoclonal antibodies
INVIVYD HAS A PLATFORM DESIGNED TO RAPIDLY DELIVER A STREAM OF MONOCLONAL ANTIBODIES TO KEEP PACE WITH VIRAL EVOLUTION Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat ~10 million B Cells MINE Mine human antibody
Slide 9: VYD222: engineered for broad activity and prolonged utility
VYD222: ENGINEERED FOR BROAD ACTIVITY AND PROLONGED UTILITY VYD222 is engineered from adintrevimab (ADG20), a product candidate that Invivyd took from IND to pivotal data in 16 months Designed for: • High potency VYD222 • Lack of polyreactivity • Long half-life • Developability • Potential to resist
Slide 10: Ongoing Phase 1 trial of VYD222 with initial data readouts planned for Q2 2023
ONGOING PHASE 1 TRIAL OF VYD222 WITH INITIAL DATA READOUTS PLANNED FOR Q2 2023 VYD222 Dose A (n=8) VYD222 Dose B (n=8) 8:2 Randomization Healthy Adult (VYD222:Placebo) VYD222 Dose C (n=8) Volunteers (N=30) Placebo (n=6) Day 1 (Dosing) Month 12 (Last visit) Early Safety, Tolerability, Long Term PK &
Slide 11: Serum virus neutralizing antibody titers may predict protection against symptomatic COVID-19
SERUM VIRUS NEUTRALIZING ANTIBODY TITERS MAY PREDICT PROTECTION AGAINST SYMPTOMATIC COVID-19 Serum neutralizing titers (either mAb or vaccine-induced) correlate with protection against symptomatic SARS-CoV-2 infection across multiple variants Vaccines Reported protection against symptomatic COVID-19
Slide 12: Regulators and government agencies seeking to support development of COVID-19 monoclonal antibodies
REGULATORS AND GOVERNMENT AGENCIES ARE SEEKING TO SUPPORT DEVELOPMENT OF MONOCLONAL ANTIBODIES FOR COVID-19 Regulators & government agencies are considering Invivyd is focused on rapidly and perpetually strategies to accelerate mAb development timelines developing mAb candidates Project Next Gen: $5
Slide 13: Aims to work with global regulators to establish a new paradigm
INVIVYD AIMS TO WORK WITH GLOBAL REGULATORS TO ESTABLISH A NEW PARADIGM TO KEEP PACE WITH VIRAL EVOLUTION Invivyd envisions a future development path for viral-directed mAbs that is similar to the platform-based approach used to periodically modify flu and SARS-CoV-2 vaccines THE PAST TODAY VISION F
Slide 14: VYD222 is one of many antibodies in Invivyd's robust pipeline
VYD222 IS ONE OF MANY ANTIBODIES IN INVIVYD’S ROBUST PIPELINE DEVELOPMENT STATUS PROGRAMS PLATFORM INDICATION(S) STATUS DISCOVERY/ IND-ENABLING PHASE 1 PHASE 2 PHASE 3 PRECLINICAL CORONAVIRUSES Initial Ph 1 VYD222 mAb Prevention readouts expected in Q2 2023 Engineering Prevention or VYD224 mAb varia
Slide 15: Company well capitalized to develop lead candidate and additional pipeline assets
COMPANY WELL CAPITALIZED TO DEVELOP LEAD CANDIDATE & ADDITIONAL PIPELINE ASSETS Total fully diluted shares of Cash Position: common stock Cash, cash equivalents and Planned cash runway outstanding* as of marketable securities were into H2 2024 $372 million as of December 31, 2022: December 31, 2022
Slide 16: Management team with track record of success
MANAGEMENT TEAM WITH TRACK RECORD OF SUCCESS Stacy Price, M.S. Jeremy Gowler Dave Hering Robert Allen, Ph.D. Chief Technology & Chief Operating & Chief Executive Officer Chief Scientific Officer Manufacturing Officer Commercial Officer & Director Peter C. Schmidt, M.D., MSc Jill Andersen, J.D. Fred
Slide 17: Thank you
a > 2 > 2 ' y Le THANK YOU », Fy,